Corporate / M&A

Capital Markets

Financial Market Regulation

Homburger News

Share-Image Teamplate Deals-and-Cases

On November 20, 2024, Sunshine SwissCo AG (a consortium led by EQT), the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as the Sellers) announced the launch of an accelerated bookbuilding process to professional investors in Switzerland and to qualified investors outside Switzerland, which led to the successful placement of 16,000,000 shares in Galderma Group AG (Galderma) at a price of CHF 80 per share (the Placement), raising a total of ca. CHF 1.28 bn in total.
The Sellers will remain shareholders of 54.48% of the share capital of Galderma. EQT’s representation on the Board of Directors of Galderma remains unchanged as a result of the Placement. Such Placement will broaden Galderma&#8217;s shareholder base and free float. In connection therewith, the Sellers have agreed to a 90-day lock-up period, subject to certain customary exceptions, with respect to their remaining holding in Galderma.
The Placement is expected to be settled on November 25, 2024. Following the Placement, no changes to the Galderma board of directors and its governance are envisioned.
Homburger acted as transaction counsel to EQT.
The Homburger team was led by Frank Gerhard (Corporate / M&amp;A, Capital Markets) and included Lorenzo Togni, Estelle Piccard and Héloïse de Jamblinne (all Corporate / M&amp;A, Capital Markets), Micha Fankhauser (Financial Market Regulation) as well as Stefan Oesterhelt (Tax).

Homburger advises EQT on the sale of 6.73% of Galderma's share capital via an accelerated bookbuilding process

Molecular Partners

On October 25, 2024, Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics announced that it had priced an underwritten offering of 3,642,988 American Depositary Shares (ADSs) representing 3,642,988 new shares at an offering price of USD 5.49 per ADS amounting to gross proceeds of USD 20 m. The offering included participation from a new investor HBM Healthcare Investments Ltd, which is a leading healthcare investor, as well as multiple existing investors.
Molecular Partners currently intends to use the net proceeds from this offering for the development and expansion of its radiopharmaceutical pipeline and platform (Radio-DARPin Therapeutics) and other general corporate purposes.
The Homburger team was led by Dieter Gericke and Karin Mattle (both Corporate / M&amp;A, Capital Markets) and included Stefan Oesterhelt (Tax), Lorenzo Togni, Romain Fakhoury and Hans Glent Abildgaard (all Corporate / M&amp;A, Capital Markets).

Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary Shares

Homburger advises EQT on the sale of 6% of Galderma's share capital via an accelerated bookbuilding process

On September 3, 2024, Sunshine SwissCo AG (a consortium led by EQT), the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as the Sellers) announced the launch of an accelerated bookbuilding process to professional investors in Switzerland and to qualified investors outside Switzerland, which led to the successful placement of 14,273,859 shares in Galderma Group AG (Galderma) at a price of CHF 75 per share (the Placement), raising a total of ca. CHF 1.07 bn in total.
The Sellers will remain shareholders of 61.21% of the share capital of Galderma. EQT’s representation on the Board of Directors of Galderma remains unchanged as a result of the Placement. Such Placement will broaden Galderma&#8217;s shareholder base and free float. In connection therewith, the Sellers have agreed to a 90-day lock-up period, subject to certain customary exceptions, with respect to their remaining holding in Galderma.
The Placement is expected to be settled on September 6, 2024. Following the Placement, no changes to the Galderma board of directors and its governance are envisioned.
Homburger acted as transaction counsel to EQT. The Homburger team was led by Frank Gerhard (Corporate / M&amp;A, Capital Markets) and included Lorenzo Togni (Corporate / M&amp;A, Capital Markets), Estelle Piccard, Simone Schmid and Héloïse de Jamblinne (all Corporate / M&amp;A), Micha Fankhauser (Financial Market Regulation) as well as Stefan Oesterhelt (Tax).

Lorenzo
Togni

Homburger advises EQT on the sale of 6.73% of Galderma's share capital via an accelerated bookbuilding process

Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary Shares

Homburger advises EQT on the sale of 6% of Galderma's share capital via an accelerated bookbuilding process

Indicative Timeline for an IPO (Switzerland)

Moving the Goalposts between Launch and Pricing oder Der Prospektnachtrag beim IPO unter bisherigem und zukünftigem Recht

The future of equity capital markets transactions in Switzerland: what issuers of equity instruments should know about the new Swiss prospectus regime

Join the Team

Lorenzo Togni

Career

Languages

Bar Registration

Teams

LorenzoTogni

Homburger advises EQT on the sale of 6.73% of Galderma's share capital via an accelerated bookbuilding process

Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary Shares

Homburger advises EQT on the sale of 6% of Galderma's share capital via an accelerated bookbuilding process

Indicative Timeline for an IPO (Switzerland)

Moving the Goalposts between Launch and Pricing oder Der Prospektnachtrag beim IPO unter bisherigem und zukünftigem Recht

The future of equity capital markets transactions in Switzerland: what issuers of equity instruments should know about the new Swiss prospectus regime

Join the Team

Lorenzo Togni

Career

Languages

Bar Registration

Teams

Lorenzo
Togni